Waltz Health Acquisition, Valuation, Funding & Investors

Waltz Health was acquired by EVERSANA in August 2025.

Waltz Health acquisition price

Undisclosed

Acquired by EVERSANA · Aug 2025

Cumulative funding Waltz Health raised

$56M

across 3 funding rounds

Key investors in Waltz Health

  • GV
  • The Blue Venture Fund
  • Define Ventures
  • Echo Health Ventures
  • Twine Ventures
  • Byers Capital

Waltz Health Overview

About Waltz Health

Waltz Health is a digital health company that builds software-powered drug-price marketplaces and prescription routing tools. Its platforms connect patients, health insurers, self-insured employers, governments, pharmacy benefit managers and pharmacies so that prescription care decisions are based on transparent pricing. Products include a pharmacy search marketplace for consumers, an artificial intelligence engine that routes specialty prescriptions to the lowest-cost location for payers and patients, and employer programs for high-cost drugs such as GLP-1 medicines. The company earns fees from payers, employers and pharmacy partners through subscription and usage-based arrangements. It was founded in Chicago in 2021 by Mark Thierer, a former chief executive of OptumRx, and Jonathon Thierer. In 2025 it merged into EVERSANA, a pharmaceutical commercialization services group, and its technology now operates as part of that group.


Founded

2021

HQ

United StatesChicago, IL

Status

Acquired

Customer focus

B2B

Revenue model

Services

Waltz Health Acquisition

Waltz Health was acquired by EVERSANA for an undisclosed price on 26 August 2025.

Before the acquisition Waltz Health had raised $56M across 3 funding rounds.

EVERSANA, a provider of commercialization services to pharmaceutical and biotech manufacturers and a portfolio company of Water Street Healthcare Partners, acquired and merged with Waltz Health in August 2025. The two companies said the combination forms a unified platform that joins EVERSANA's global commercialization services with Waltz Health's software-powered drug-price marketplaces and direct-to-payer model. Waltz Health co-founder and chief executive Mark Thierer, previously chief executive of OptumRx, was appointed chief executive of the combined EVERSANA. Press reports valued the combined company at $6 billion, while the price EVERSANA paid for Waltz Health was not disclosed. Sidley Austin advised Waltz Health on the merger. The companies said the deal responds to drug-pricing pressure, patient affordability and fragmented patient experiences by connecting life sciences companies directly with payers and patients through net-price models, copay optimization and lower patient abandonment. Waltz Health was founded in 2021 by Mark and Jonathon Thierer and is headquartered in Chicago. Before the merger it was backed by GV, Define Ventures, Echo Health Ventures, Blue Venture Fund, Byers Capital and Twine Ventures, and it employed about 100 people.

Waltz Health acquisition details
AcquirerDateType
  • EVERSANA
26 Aug 2025Strategic M&A

Sources: mmm-online.com, pehub.com, waltzhealth.com

Waltz Health Funding History

Waltz Health has raised a total of $56M across 3 funding rounds.

Waltz Health's first fundraising round was a $3M seed round in August 2021. The most recent completed round was a $18M undisclosed-stage round in November 2024.

Waltz Health funding rounds

Waltz Health funding rounds
DateStageInvestorsRaisedDeal Summary
Nov 2024Undisclosed stage-$18MWaltz Health raised $17.5 million in a Series A - II funding round on November 27, 2024, led by Define Ventures with participation from other investors including Google Ventures, The Blue Venture Fund, and Echo Health Ventures. The company develops AI-driven marketplaces to lower medication costs and improve consumer experiences in the pharmaceutical supply chain for payers, pharmacies, and consumers. The funding supports refining AI tools, expanding market presence, and enhancing pricing options and decision-making resources. Previously, Waltz Health launched with $35.4 million in Series A funding led by GV (Google Ventures), along with Define Ventures, Echo Health Ventures, Blue Venture Fund, Byers Capital, Twine Ventures, and individual investors. Its initial product, Marketplace Search, is a search engine for pharmacies that uses data from drug discount programs to identify lower-cost medications. The company has raised a total of $55.9 million over multiple rounds.
Apr 2022Series AGV (lead); The Blue Venture Fund; Byers Capital; Define Ventures; Twine Ventures; Echo Health Ventures$35MWaltz Health is a prescription-focused startup that launched in April 2022 with $35.4 million in Series A funding led by GV, with participation from Define Ventures, Echo Health Ventures, Blue Venture Fund, Byers Capital, Twine Ventures, and individual healthcare executives. The company's initial product, Marketplace Search, is a search engine for pharmacies that uses data from drug discount programs to help consumers find lower-cost medications, aiming to realign incentives in the drug supply chain, lower prices, and empower consumers. Co-founded by Mark Thierer, former CEO of OptumRx, Waltz Health plans to use the capital to scale operations, hire team members, and develop products, with upcoming partnerships with major pharmacy chains. The startup leverages insider knowledge of the pharmacy benefit manager (PBM) market and a technology team to deliver savings through software solutions addressing pharmaceutical challenges for consumers and payers. GV's Ben Robbins highlighted the company's transparent, patient-centric approach and leadership's understanding of the sector's complexities, positioning it to impact the prescription care market. Subsequently, Waltz Health raised additional funding, including a Series A - II of $17.5M in November 2024, bringing total raised to $55.9M over multiple rounds, before merging with EVERSANA in August 2025 to enhance pharma commercialization and drug access.
Aug 2021Seed-$3MWaltz Health, a Chicago-based digital health company founded in 2021 by Mark Thierer and Jonathon Thierer, raised a seed round of about USD 3 million in August 2021, according to its regulatory filing for the equity sale. The investors in the round were not named publicly. Waltz Health builds AI-driven marketplaces that give consumers price comparisons and information on prescription drugs and help payers manage pharmacy benefits. Its first product, Marketplace Search, is a white-labeled tool that pharmacies offer their customers to compare prescription prices. Mark Thierer previously served as chief executive of OptumRx. The company later raised a Series A of USD 35.4 million led by GV in April 2022.

Who has invested in Waltz Health?

6 investors have backed Waltz Health across its funding rounds, including GV, The Blue Venture Fund, Define Ventures, Echo Health Ventures, Twine Ventures and Byers Capital.

Lead investors include GV.


Waltz Health Investors

Investors in Waltz Health by funding rounds participated
InvestorHQRoundsRoleFirst check
The Blue Venture FundUnited StatesChicago, IL1ParticipantApr 2022
GVUnited StatesSan Francisco, CA1LeadApr 2022
Byers CapitalUnited StatesSan Francisco, CA1ParticipantApr 2022
Define VenturesUnited StatesSan Francisco, CA1ParticipantApr 2022

This data is available for Pro users. Sign up to see all 6 Waltz Health investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Waltz Health Competitors

Waltz Health competitors include listed companies like UnitedHealth Group, Molina Healthcare, HealthEquity and WEX, and private ones like Spring Health and Judi Health.

Public and private companies comparable to Waltz Health
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
UnitedHealth GroupUnited StatesUnited StatesPublicly listed$448B$23B$353B0.9x
Molina HealthcareUnited StatesUnited StatesPublicly listed$45B$976M$11B0.1x
HealthEquityUnited StatesUnited StatesPublicly listed$1.3B$478M$8.6B6.7x
WEXUnited StatesUnited StatesPublicly listed$2.7B$992M$6B2.1x
Spring HealthUnited StatesNew York City, NYPrivate$125M-$3.3B26.4x
Judi HealthUnited StatesNew York City, NYPrivate--$3.3B-

Waltz Health Public Comps

Waltz Health is no longer listed, but its public comps include UnitedHealth Group, Elevance Health, Cigna Group, Humana Inc., Molina Healthcare, HealthEquity, WEX, Benefit Systems, Pluxee and Clover Health.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
UnitedHealth Group$448B$23B0.9x0.9x17.6x13.4x
Elevance Health$199B$9.7B0.5x0.5x9.5x8.6x
Cigna Group$274B$12B0.3x0.3x6.5x5.9x
Humana Inc.$130B$3B0.4x0.3x17.3x17.1x
Molina Healthcare$45B$976M0.1x0.1x6.4x8.2x
HealthEquity$1.3B$478M7.1x6.7x19.4x15.0x
WEX$2.7B$992M2.3x2.1x6.1x4.6x
Benefit Systems$1.2B$357M5.1x4.1x16.4x13.8x

This data is available for Pro users. Sign up to see all Waltz Health competitors and their valuation data.

Start Free Trial

Common questions about Waltz Health

When was Waltz Health founded?Waltz Health was founded in 2021.
Where is Waltz Health headquartered?Waltz Health is headquartered in Chicago, IL, United States.
Is Waltz Health publicly listed?No, Waltz Health was acquired by EVERSANA in August 2025.
Who acquired Waltz Health?Waltz Health was acquired by EVERSANA in August 2025.
How much funding has Waltz Health raised?Waltz Health has raised $56M across 3 funding rounds.
What was Waltz Health's last funding round?Waltz Health's last funding round was a $18M undisclosed-stage round in November 2024.
Who are Waltz Health's investors?Waltz Health's investors include The Blue Venture Fund, GV, Byers Capital, Define Ventures, Twine Ventures and Echo Health Ventures.
Which companies are comparable to Waltz Health?Companies comparable to Waltz Health include UnitedHealth Group, Molina Healthcare, HealthEquity, WEX, Spring Health and Judi Health.

See companies similar to Waltz Health

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial